|
1
|
Fattizzo B and Barcellini W: Autoimmune
cytopenias in chronic lymphocytic leukemia: Focus on molecular
aspects. Front Oncol. 9:14352020. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barcellini W, Capalbo S, Agostinelli RM,
Mauro FR, Ambrosetti A, Calori R, Cortelezzi A, Laurenti L,
Pogliani EM, Pedotti P, et al: Relationship between autoimmune
phenomena and disease stage and therapy in B-cell chronic
lymphocytic leukemia. Haematologica. 91:1689–1692. 2006.PubMed/NCBI
|
|
3
|
Fallah M, Liu X, Ji J, Försti A, Sundquist
K and Hemminki K: Autoimmune diseases associated with non-Hodgkin
lymphoma: A nationwide cohort study. Ann Oncol. 25:2025–2030. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Visco C, Ruggeri M, Laura Evangelista M,
Stasi R, Zanotti R, Giaretta I, Ambrosetti A, Madeo D, Pizzolo G
and Rodeghiero F: Impact of immune thrombocytopenia on the clinical
course of chronic lymphocytic leukemia. Blood. 111:1110–1116. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Mittal S, Blaylock MG, Culligan DJ, Barker
RN and Vickers MA: A high rate of CLL phenotype lymphocytes in
autoimmune hemolytic anemia and immune thrombocytopenic purpura.
Haematologica. 93:151–152. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kyle RA and Lust JA: Monoclonal
gammopathies of undetermined significance. Semin Heamatol.
26:176–200. 1989.PubMed/NCBI
|
|
7
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2019. CA Cancer J Clin. 69:7–34. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Liu Y and Barta SK: Diffuse large B-cell
lymphoma: 2019 Update on diagnosis, risk stratification, and
treatment. Am J Hematol. 94:604–616. 2019. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Papageorgiou SG, Thomopoulos TP, Spathis
A, Bouchla A, Glezou I, Stavroulaki G, Gkontopoulos K, Bazani E,
Foukas PG and Pappa V: Prognostic significance of monoclonal
gammopathy in diffuse large B-cell lymphoma. Hematol Oncol.
37:634–637. 2019. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Harris NL, Jaffe ES, Diebold J, Flandrin
G, Muller-Hermelink HK, Vardiman J, Lister TA and Bloomfield CD:
World Health Organization classification of neoplastic diseases of
the hematopoietic and lymphoid tissues: Report of the clinical
advisory committee meeting. Airlie House, Virginia, November 1997.
J Clin Oncol. 17:3835–3849. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Hans CP, Weisenburger DD, Greiner TC,
Gascoyne RD, Delabie J, Ott G, Müller-Hermelink HK, Campo E,
Braziel RM, Jaffe ES, et al: Confirmation of the molecular
classification of diffuse large B-cell lymphoma by
immunohistochemistry using a tissue microarray. Blood. 103:275–282.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Cooper N: State of the art-how I manage
immune thrombocytopenia. Br J Haematol. 177:39–54. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Zufferey A, Kapur R and Semple JW:
Pathogenesis and therapeutic mechanisms in immune thrombocytopenia
(ITP). J Clin Med. 6:162017. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Olsson B, Ridell B, Jernås M and Wadenvik
H: Increased number of B-cells in the red pulp of the spleen in
ITP. Ann Hematol. 91:271–277. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Chen JF, Yang LH, Chang LX, Feng JJ and
Liu JQ: The clinical significance of circulating B cells secreting
anti-glycoprotein IIb/IIIa antibody and platelet glycoprotein
IIb/IIIa in patients with primary immune thrombocytopenia.
Hematology. 17:283–290. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Li X, Zhong H, Bao W, Boulad N,
Evangelista J, Haider MA, Bussel J and Yazdanbakhsh K: Defective
regulatory B-cell compartment in patients with immune
thrombocytopenia. Blood. 120:3318–3325. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Aslam R, Segel GB, Burack R, Spence SA,
Speck ER, Guo L and Semple JW: Splenic lymphocyte subtypes in
immune thrombocytopenia: Increased presence of a subtype of
B-regulatory cells. Br J Haematol. 173:159–160. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Min YN, Wang CY, Li XX, Hou Y, Qiu JH, Ma
J, Shao LL, Zhang X, Wang YW, Peng J, et al: Participation of
B-cell-activating factor receptors in the pathogenesis of immune
thrombocytopenia. J Thromb Haemost. 14:559–571. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Miltiadous O, Hou M and Bussel JB:
Identifying and treating refractory ITP: Difficulty in diagnosis
and role of combination treatment. Blood. 135:472–490. 2020.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
De Rossi G, Granati L, Girelli G, Gandolfo
G, Arista MC, Martelli M, Conti L, Marini R, La Tagliata R, Leone
R, et al: Incidence and prognostic significance of autoantibodies
against erythrocytes and platelets in chronic lymphocytic leukemia
(CLL). Nouv Rev Fr Hematol (1978). 30:403–406. 1988.PubMed/NCBI
|
|
21
|
De Rossi G, Granati L, Girelli G, Gandolo
G, Perrone P, Martelli M, Conti L, Marini R, Pastorelli D, Coluzzi
S, et al: Prognostic value of autoantibodies against erythrocytes
and platelets in chronic lymphocytic leukemia (CLL). Tumori.
77:100–104. 1991. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Garvey MB and Freedman J: Indirect
platelet radioactive antiglobulin test in patients with
lymphoproliferative disease. J Lab Clin Med. 107:123–128.
1986.PubMed/NCBI
|
|
23
|
Liu EB, Zhang PH, Li ZQ, Sun Q, Yang QY,
Fang LH, Sun FJ and Qiu LG: Clinicopathologic features of
lymphoplasmacytic lymphoma. Zhonghua Bing Li Xue Za Zhi.
39:308–312. 2010.(In Chinese). PubMed/NCBI
|
|
24
|
Lechman HA, Lehman LO, Rutagi PK, Rustgi
RN, Plunkett RW, Farolino DL, Conway J and Logue GL:
Complement-mediated autoimmune thrombocytopenia. Monoclonal IgM
antiplatelet antibody associated with lymphoreticular malignant
disease. N Engl J Med. 316:194–198. 1987.
|
|
25
|
Kuznetsov AI, Ivanov AL, Idelson LI and
Mazurov AV: Mechanisms of thrombocytopenia in patients with
lymphoproliferative diseases. Eur J Haematol. 49:113–118. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Myers TJ, Kim BK, Steiner M and Baldini
MG: Platelet-associated complement C3 in immune thrombocytopenic
purpura. Blood. 59:1023–1028. 1982. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Kaiho T, Miyazaki M, Iinuma K, Ito H,
Koyama T, Nakagawa K and Nakajima N: Long-term prognosis of
idiopathic thrombocytopenic purpura treated by partial splenic
embolization. Nihon Geka Gakkai Zasshi. 94:383–393. 1993.(In
Japanese). PubMed/NCBI
|
|
28
|
Vardhana SA, Sauter CS, Matasar MJ,
Zelenetz AD, Galasso N, Woo KM, Zhang Z and Moskowitz CH: Outcomes
of primary refractory diffuse large B-cell lymphoma (DLBCL) treated
with salvage chemotherapy and intention to transplant in the
rituximab era. Br J Haematol. 176:591–599. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Coiffier B, Thieblemont C, Van Den Neste
E, Lepeu G, Plantier I, Castaigne S, Lefort S, Marit G, Macro M,
Sebban C, et al: Long-term outcome of patients in the LNH-98.5
trial, the first randomized study comparing rituximab-CHOP to
standard CHOP chemotherapy in DLBCL patients: A study by the Groupe
d'Etudes des Lymphomes de l'Adulte. Blood. 116:2040–2045. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Witzig TE, Maurer MJ, Stenson MJ, Allmer
C, Macon W, Link B, Katzmann JA and Gupta M: Elevated serum
monoclonal and polyclonal free light chains and interferon
inducible protein-10 predicts inferior prognosis in untreated
diffuse large B-cell lymphoma. Am J Hematol. 89:417–422. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Kaseb H, Annamaraju P and Babiker HM:
Monoclonal gammopathy of undetermined significance. StatPearls
[Internet] Treasure Island (FL): StatPearls Publishing; 2023
|
|
32
|
Wright DH: Malignant lymphomas other than
Hodgkin's disease: Histology, cytology, ultrastructure, immunology.
J Clin Pathol. 32:4141979. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Economopoulos T, Papageorgiou S, Pappa V,
Papageorgiou E, Valsami S, Kalantzis D, Xiros N, Dervenoulas J and
Raptis S: Monoclonal gammopathies in B-cell non-Hodgkin's
lymphomas. Leuk Res. 27:505–508. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Kim YR, Kim SJ, Cheong JW, Kim Y, Jang JE,
Lee JY, Min YH, Song JW, Yang WI and Kim JS: Monoclonal and
polyclonal gammopathy measured by serum free light chain and
immunofixation subdivide the clinical outcomes of diffuse large
B-cell lymphoma according to molecular classification. Ann Hematol.
93:1867–1877. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Li Y, Wang L, Zhu HY, Liang JH, Wu W, Wu
JZ, Xia Y, Fan L, Li JY and Xu W: Prognostic significance of serum
immunoglobulin paraprotein in patients with diffuse large B cell
lymphoma. Br J Haematol. 182:131–134. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Zhang Y, Wei Z, Li J, Gao R and Liu P:
Monoclonal gammopathies regardless of subtypes are associated with
poor prognosis of diffuse large B-cell lymphoma: A STROBE-compliant
article. Medicine (Baltimore). 97:e117192018. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Cox MC, Di Napoli A, Fabbri A, Cencini E
and Ruco L: The significance of serum immunoglobulin paraprotein in
diffuse large B-cell lymphoma. Br J Haematol. 182:741–742. 2018.
View Article : Google Scholar : PubMed/NCBI
|
